See more : Ahresty Corporation (5852.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cybin Inc. (CYBN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cybin Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hubei Yihua Chemical Industry Co., Ltd. (000422.SZ) Income Statement Analysis – Financial Results
- Seagen Inc. (SGEN) Income Statement Analysis – Financial Results
- Skyworks Solutions, Inc. (SWKS) Income Statement Analysis – Financial Results
- Saptak Chem and Business Limited (SCBL.BO) Income Statement Analysis – Financial Results
- China Chunlai Education Group Co., Ltd. (1969.HK) Income Statement Analysis – Financial Results
Cybin Inc. (CYBN)
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 864.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 424.00K | 251.00K | 168.00K | 664.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -424.00K | -251.00K | -168.00K | 200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 23.15% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.36M | 26.15M | 17.59M | 3.30M | 321.60K | 0.00 | 0.00 |
| General & Administrative | 29.80M | 24.49M | 44.79M | 22.48M | 1.36M | 0.00 | 0.00 |
| Selling & Marketing | 2.79M | 881.00K | 1.47M | 4.95M | 117.60K | 0.00 | 0.00 |
| SG&A | 46.47M | 25.37M | 46.25M | 27.42M | 1.63M | 80.52K | 127.22K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -482.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 78.84M | 51.52M | 63.84M | 30.72M | 1.94M | 80.52K | 127.22K |
| Cost & Expenses | 78.84M | 51.52M | 63.84M | 31.39M | 1.94M | 80.52K | 127.22K |
| Interest Income | 619.00K | 603.00K | 241.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 241.00K | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 260.00K | 251.00K | 168.00K | 49.00K | 1.95M | 161.14K | 0.00 |
| EBITDA | -78.58M | -51.29M | -63.67M | -32.16M | 9.60K | -80.52K | -127.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,520.25% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.84M | -54.94M | -63.60M | -30.46M | -1.95M | -80.52K | -127.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,525.93% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 756.00K | 4.03M | -3.79M | -1.19M | 9.60K | -20.00K | 4.00 |
| Income Before Tax | -78.08M | -47.49M | -67.63M | -32.22M | -1.94M | -100.52K | -127.22K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.45M | 3.79M | 10.00K | 9.60 | -161.14K | 0.00 |
| Net Income | -78.08M | -40.04M | -71.42M | -32.22M | -1.94M | -100.52K | -127.22K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| EPS | -9.50 | -0.22 | -0.43 | -0.32 | -0.05 | -0.01 | -0.01 |
| EPS Diluted | -9.41 | -0.22 | -0.43 | -0.32 | -0.04 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 8.22M | 185.43M | 167.29M | 100.01M | 40.50M | 13.89M | 13.89M |
| Weighted Avg Shares Out (Dil) | 8.30M | 185.43M | 167.29M | 100.01M | 49.98M | 13.89M | 13.89M |
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”
Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”. Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled,...
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin's Chief Medical Officer,...
Cybin Provides Corporate Update on Upcoming Clinical Milestones
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. “We...
'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure.
Cybin Announces Completion of Previously Announced Share Consolidation
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of...
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of...
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer,...
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ: GPCR ), for example.
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on...
Source: https://incomestatements.info
Category: Stock Reports